Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity

• Published in: BMC research notes Vol. 11; no. 1; p. 472
• Main Authors: Tada, Rui, Hidaka, Akira, Kiyono, Hiroshi, Kunisawa, Jun, Aramaki, Yukihiko
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.07.2018; BioMed Central; BMC
• Subjects: Adjuvants, Immunologic; Administration, Intranasal; Animals; Antibody Formation; Antigens; Care and treatment; Cationic liposome; Cations; Cholesterol - analogs & derivatives; Colony-stimulating factor; Communicable diseases; Cytokines; Experiments; Fatty Acids, Monounsaturated; Female; Gene expression; Genetic aspects; Granulocyte-macrophage colony stimulating factor; Granulocyte-Macrophage Colony-Stimulating Factor - metabolism; Granulocytes; Humans; Infectious diseases; Intranasal administration; Intranasal immunization; Japan; Laboratory animals; Lipids; Liposomes; Liposomes - administration & dosage; Liposomes - immunology; Mice; Mucosa; Mucosal adjuvant; Mucous membrane; Nasal Mucosa - immunology; Nasal Mucosa - metabolism; Prevention; Proteins; Quaternary Ammonium Compounds; Rats; Research Note; Tokyo; Vaccination; Vaccines; Tokyo; Japan; Mucosal adjuvant; Intranasal immunization; Cationic liposome; Granulocyte–macrophage colony-stimulating factor
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-018-3591-3

Infectious diseases remain a threat to human life. Vaccination against pathogenic microbes is a primary method of treatment as well as prevention of infectious diseases. Particularly mucosal vaccination is a promising approach to fight against most infectious diseases, because mucosal surfaces are a major point of entry for most pathogens. We recently developed an effective mucosal adjuvant of cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl] (DC-chol) (DOTAP/DC-chol liposomes). However, the mechanism(s) underlying the mucosal adjuvant effects exerted by the cationic liposomes have been unclear. In this study, we investigated the role of granulocyte-macrophage colony-stimulating factor (GM-CSF), which was reported to act as a mucosal adjuvant, on the mucosal adjuvant activities of DOTAP/DC-chol liposomes when administered intranasally to mice. Here, we show that, although intranasal vaccination with cationic liposomes in combination with antigenic protein elicited GM-CSF expression at the site of administration, blocking GM-CSF function by using an anti-GM-CSF neutralizing antibody did not alter antigen-specific antibody production induced by DOTAP/DC-chol liposomes, indicating that GM-CSF may not contribute to the mucosal adjuvant activity of the cationic liposomes when administered intranasally.